{"query":{"id":null,"referenceGenome":"GRCh37","hugoSymbol":"BRAF","entrezGeneId":673,"alteration":"V600E","alterationType":null,"svType":null,"tumorType":null,"consequence":"missense_variant","proteinStart":600,"proteinEnd":600,"hgvs":"7:g.140453135_140453136delinsCT","hgvsInfo":null,"canonicalTranscript":"ENST00000288602"},"geneExist":true,"variantExist":true,"alleleExist":true,"oncogenic":"Oncogenic","mutationEffect":{"knownEffect":"Gain-of-function","description":"The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705, 30351999).","citations":{"pmids":["25417114","20179705","23833300","26091043","26343582","12068308","30351999","25079552","28783719","19251651","15035987"],"abstracts":[]}},"highestSensitiveLevel":"LEVEL_1","highestResistanceLevel":null,"highestDiagnosticImplicationLevel":"LEVEL_Dx2","highestPrognosticImplicationLevel":null,"highestFdaLevel":"LEVEL_Fda2","otherSignificantSensitiveLevels":[],"otherSignificantResistanceLevels":[],"hotspot":true,"geneSummary":"BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers among others.","variantSummary":"The BRAF V600E mutation is known to be oncogenic.","tumorTypeSummary":"","prognosticSummary":"","diagnosticSummary":"","diagnosticImplications":[{"levelOfEvidence":"LEVEL_Dx3","alterations":["V600E"],"tumorType":{"id":611,"code":"ECD","color":"LightSalmon","name":"Erdheim-Chester Disease","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":"HDCN","level":4,"tumorForm":"LIQUID"},"pmids":["25422482","26637772"],"abstracts":[],"description":""},{"levelOfEvidence":"LEVEL_Dx2","alterations":["V600E"],"tumorType":{"id":276,"code":"HCL","color":"LimeGreen","name":"Hairy Cell Leukemia","mainType":{"id":null,"name":"Mature B-Cell Neoplasms","tumorForm":"LIQUID"},"tissue":"Lymphoid","children":{},"parent":"MBN","level":5,"tumorForm":"LIQUID"},"pmids":["23347903","25480661","22072557","21910720","22210875","25120816","22028477","21663470","26071465","22531170"],"abstracts":[],"description":""},{"levelOfEvidence":"LEVEL_Dx2","alterations":["V600E"],"tumorType":{"id":862,"code":"LCH","color":"LightSalmon","name":"Langerhans Cell Histiocytosis","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":"HDCN","level":4,"tumorForm":"LIQUID"},"pmids":["20519626","30157397","24938183","26637772"],"abstracts":[],"description":""},{"levelOfEvidence":"LEVEL_Dx3","alterations":["Oncogenic Mutations"],"tumorType":{"id":857,"code":"ETPLL","color":"LimeGreen","name":"Early T-Cell Precursor Lymphoblastic Leukemia","mainType":{"id":null,"name":"T-Lymphoblastic Leukemia/Lymphoma","tumorForm":"LIQUID"},"tissue":"Lymphoid","children":{},"parent":"TLL","level":4,"tumorForm":"LIQUID"},"pmids":["22237106"],"abstracts":[],"description":""}],"prognosticImplications":[],"treatments":[{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"}],"approvedIndications":["Dabrafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma."],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["22608338","23051966","22735384"],"abstracts":[],"description":"Dabrafenib is an orally bioavailable RAF inhibitor that is FDA-approved for use in patients with BRAF V600E- and V600K-mutant metastatic melanoma. FDA approval is based on the randomized Phase III trial in which dabrafenib (150 mg orally twice daily) was compared with dacarbazine (1000 mg/m2 intravenously every three weeks) in 250 patients with BRAF V600E-mutated metastatic melanoma. Dabrafenib was associated with improved progression-free survival (median 5.1 months vs. 2.7 months with dacarbazine; hazard ratio = 0.30, p<0.0001) (PMID: 22735384). Dabrafenib may also be effective against brain metastases, as demonstrated by a Phase II trial in which approximately 40% of previously untreated and 30% of previously treated patients experienced an overall intracranial response and a separate trial in which nine out of ten patients had a reduction in the size of their brain metastases (PMID: 23051966, 22608338)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":984,"code":"","color":"","name":"","mainType":{"id":null,"name":"All Solid Tumors","tumorForm":"SOLID"},"tissue":"","children":{},"parent":null,"level":-1,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[{"id":935,"code":"","color":"SaddleBrown","name":"","mainType":{"id":null,"name":"Colorectal Cancer","tumorForm":"SOLID"},"tissue":"Bowel","children":{},"parent":null,"level":0,"tumorForm":"SOLID"}],"pmids":["32758030","27283860","23020132","32818466","25399551","34838156"],"abstracts":[{"link":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318","abstract":"Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020."},{"link":"https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002","abstract":"Bouffet et al. Abstract# LBA2002, ASCO 2022."}],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). In the randomized, Phase II study of dabrafenib and trametinib in 110 patients with BRAF V600–mutant pediatric low-grade glioma (dabrafenib + trametinib treatment, n=37; carboplatin + vincristine treatment, n=37), the overall response rate was 47% (95% CI= 35%-59%) with dabrafenib and trametinib and 11% (95% CI= 3%-25%) with carboplatin and vincristine, and the progression-free survival was 20.1 months (95% CI= 12.8 mo-not estimable) with dabrafenib and trametinib and 7.4 months (95% CI= 3.6-11.8 mo) with carboplatin and vincristine (Abstract: Bouffet et al. Abstract# LBA2002, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002). FDA approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":["Dabrafenib in combination with trametinib is FDA-approved for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options."],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":409,"code":"THAP","color":"Teal","name":"Anaplastic Thyroid Cancer","mainType":{"id":null,"name":"Thyroid Cancer","tumorForm":"SOLID"},"tissue":"Thyroid","children":{},"parent":"THYROID","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["29072975"],"abstracts":[],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":897,"code":"","color":"MIXED","name":"","mainType":{"id":null,"name":"Hepatobiliary Cancer","tumorForm":"SOLID"},"tissue":"MIXED","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["32758030","37059834","27283860","23020132","32818466","25399551","34838156"],"abstracts":[{"link":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318","abstract":"Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020."}],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In the Phase II ROAR basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutated rare cancers (biliary tract cancer, n=43), the overall response rate was 53%, the median progression-free survival was nine months (95% CI = 5.5, 9.4) and the median overall survival was 13.5 months (95% CI = 10.4, 17.6) (PMID: 37059834). Of the 43 patients with biliary tract cancer, 53% of patients (23/43) had a partial response and 37% (16/43) had stable disease (PMID: 37059834). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (n=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":393,"code":"BILIARY_TRACT","color":"Green","name":"Biliary Tract","mainType":{"id":null,"name":"Biliary Tract Cancer, NOS","tumorForm":"SOLID"},"tissue":"Biliary Tract","children":{},"parent":"TISSUE","level":1,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["32758030","37059834","27283860","23020132","32818466","25399551","34838156"],"abstracts":[{"link":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318","abstract":"Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020."}],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In the Phase II ROAR basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutated rare cancers (biliary tract cancer, n=43), the overall response rate was 53%, the median progression-free survival was nine months (95% CI = 5.5, 9.4) and the median overall survival was 13.5 months (95% CI = 10.4, 17.6) (PMID: 37059834). Of the 43 patients with biliary tract cancer, 53% of patients (23/43) had a partial response and 37% (16/43) had stable disease (PMID: 37059834). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (n=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":259,"code":"LGGNOS","color":"Gray","name":"Low-Grade Glioma, NOS","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["37733309"],"abstracts":[],"description":"Dabrafenib, a small molecule RAF inhibitor, and trametinib, a small molecule MEK1/2 inhibitor, are FDA-approved in combination for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. FDA approval is based on the results of the Phase II Study CDRB436G2201 (NCT02684058) of dabrafenib plus trametinib versus carboplatin plus vincristine in 110 patients with BRAF V600-mutant LGG, as assessed by local or central laboratory tests. In the Phase II Study CDRB436G2201 (NCT02684058), the dabrafenib plus trametinib cohort (n=73 [n=70, V600E; n=3, other]) demonstrated an overall response rate (ORR) of 47% (95% CI=35-59), with a 3% (n=2) complete response (CR) rate, a 44% (n=32) partial response (PR) rate and a 41% (n=30) stable disease (SD) rate, and a median duration of response (DOR) of 20.3 months (95% CI=12.0-NE) while the chemotherapy cohort (n=37 [n=35, V600E; n=1, other; n=1, nonmutant]) demonstrated an ORR of 11% (95% CI=3-25) (OR=7.19 [95% CI=2.30-22.40]; RR=4.31 [95% CI=1.70-11.20]; p<0.001), with a 3% (n=1) CR rate, an 8% (n=3) PR rate and a 41% (n=15) SD rate, and a median DOR that was not estimable (95% CI=6.6-NE) (PMID: 37733309)."},{"alterations":["V600E","V600K"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":["Dabrafenib + Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["31171876","28891408","31171878","31171879","25265492","25287827","29361468","28991513","23020132","25399551"],"abstracts":[],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. FDA approval of dabrafenib in combination with trametinib was based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"},{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":["Dabrafenib and trametinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":876,"code":"","color":"Gainsboro","name":"","mainType":{"id":null,"name":"Non-Small Cell Lung Cancer","tumorForm":"SOLID"},"tissue":"Lung","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["28919011","27283860"],"abstracts":[],"description":"Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. FDA approval was based on a Phase II, multicenter, non-randomized, open-label study of dabrafenib in combination with trametinib in patients with chemotherapy-pretreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, in which 36 of 57 patients (63%) achieved overall tumor response, with two patients experiencing durable complete responses and 34 patients having durable partial responses (PMID: 27283860). In the third arm of that study, which included patients with untreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, 23 of 26 patients (64%, 95% CI 46-79) had an overall response, with two patients (6%) having durable complete response and 21 (58%) having partial response (PMID: 28919011)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib"},{"ncitCode":"C1723","drugName":"Cetuximab"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":935,"code":"","color":"SaddleBrown","name":"","mainType":{"id":null,"name":"Colorectal Cancer","tumorForm":"SOLID"},"tissue":"Bowel","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["31566309"],"abstracts":[],"description":"Encorafenib, a small molecule RAF-targeted inhibitor, and cetuximab, an anti-EGFR antibody, are FDA-approved in combination for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. BRAF V600E mutations for treatment with encorafenib plus cetuximab were detected by the FoundationOne Liquid CDx, the MI Cancer Seek assay or the therascreen BRAF V600E RGQ PCR Kit. FDA approval was based on results of the Phase III BEACON (NCT02928224) study of encorafenib plus cetuximab (n=220) versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy (n=221) in 665 patients with BRAF V600E-mutant colorectal cancer. \n\nIn the Phase III BEACON (NCT02928224) trial, the overall response rate (complete or partial response) was 20% (95% CI=13-29) in the doublet arm versus 2% (95% CI=<1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the chemotherapy arm (95% CI= 4.8-6.6) (PMID: 31566309)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib"},{"ncitCode":"C1723","drugName":"Cetuximab"},{"ncitCode":"C11197","drugName":"FOLFOX Regimen"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":935,"code":"","color":"SaddleBrown","name":"","mainType":{"id":null,"name":"Colorectal Cancer","tumorForm":"SOLID"},"tissue":"Bowel","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["39863775"],"abstracts":[],"description":"Encorafenib, a small molecule RAF-targeted inhibitor, and cetuximab, an anti-EGFR antibody, are FDA-approved in combination with FOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. BRAF V600E mutations were detected by the therascreen BRAF V600E RGQ PCR Kit. FDA approval was based on the results of the Phase III BREAKWATER (NCT04607421) trial of encorafenib plus cetuximab versus encorafenib plus cetuximab with FOLFOX6 versus standard-of-care in 479 patients with BRAF V600E-mutant mCRC.\n\nIn the Phase III BREAKWATER (NCT04607421) trial, the encorafenib plus cetuximab with FOLFOX6 cohort (n=110) demonstrated an overall response rate (ORR) of 60.9% (95% CI=51.6-69.5), with a 2.7% (n=3) complete response (CR) rate, 58.2% (n=64) partial response (PR) rate and 28.2% (n=31) stable disease (SD) rate, and a median duration of response (DOR) of 13.9 months (95% CI=8.5-NE) (PMID: 39863775). The standard-of-care cohort (n=110) demonstrated an ORR of 40.0% (95% CI=31.3-49.3) (odds ratio=2.443 [95% CI=1.403-4.253; 99.8% CI=1.019-5.855]; p=0.0008), with a 1.8% (n=2) CR rate, 38.2% (n=42) PR rate and 30.9% (n=34) SD rate, and a median DOR of 11.1 months (95% CI=6.7-12.7) (PMID: 39863775)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C106254","drugName":"Tovorafenib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":259,"code":"LGGNOS","color":"Gray","name":"Low-Grade Glioma, NOS","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["37978284"],"abstracts":[],"description":"Tovorafenib is an orally available, pan-RAF small molecule inhibitor that is FDA-approved for the treatment of pediatric patients six months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FDA approval was based on the results of the Phase II FIREFLY-1 (NCT04775485) trial of tovorafenib in 76 patients (median age=8 years old [range=2-21]) with relapsed or refractory pediatric LGG harboring an activating BRAF alteration based on local laboratory testing. In the Phase II FIREFLY-1 (NCT04775485) trial, the overall RAPNO-LGG cohort demonstrated an objective response rate (ORR) of 51% (95% CI=40-63), with a 37% (n=28) partial response rate and 14% (n=11) minor response rate, a median duration of response (DOR) of 13.8 months (95% CI=11.3-NE) in 39 patients and a median progression-free survival of 13.8 months (95% CI=8.3-16.9) (PMID: 37978284). The BRAF V600E mutation subcohort (n=12) demonstrated an ORR of 50% (95% CI=21-79) and a median DOR that was not evaluable (95% CI=8.4-NE) (PMID: 37978284)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"}],"approvedIndications":["Vemurafenib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test."],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":611,"code":"ECD","color":"LightSalmon","name":"Erdheim-Chester Disease","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":"HDCN","level":4,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["26287849","29188284"],"abstracts":[],"description":"Vemurafenib is an orally available, small molecule RAF-targeted inhibitor that is FDA-approved for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation. FDA approval was based on the results of the Phase II VE-BASKET (NCT01524978) trial of vemurafenib in 26 patients with BRAF V600-mutant non-melanoma cancers (n=22, ECD; n=4, Langerhans cell histiocytosis [LCH]).\nIn the Phase II VE-BASKET (NCT01524978) trial, the ECD cohort demonstrated an overall response rate of 54.5% (12/22) (95% CI=32.2-75.6), with one patient (4.5%) achieving complete response and eleven patients (50%) achieving partial response, and the median progression-free survival and overall survival were not reached (PMID: 29188284, 26287849)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C106250","drugName":"Atezolizumab"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["32534646"],"abstracts":[],"description":"The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA-approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4,18.4) in the triplet arm versus 10.6 mos (95% CI=9.3,12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib"},{"ncitCode":"C84865","drugName":"Binimetinib"}],"approvedIndications":["Encorafenib and binimetinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":876,"code":"","color":"Gainsboro","name":"","mainType":{"id":null,"name":"Non-Small Cell Lung Cancer","tumorForm":"SOLID"},"tissue":"Lung","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["37270692"],"abstracts":[],"description":"Encorafenib, a small molecule inhibitor of RAF kinases, and binimetinib, a small molecule inhibitor of MEK1/2 kinases, are FDA-approved in combination for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC). FDA approval was based on the Phase II, open-label, multicenter, single-arm PHAROS study of encorafenib in combination with binimetinib in treatment-naïve (n=59) and previously treated (n=39) patients with BRAF V600E-mutant metastatic NSCLC (PMID: 37270692). In the Phase II PHAROS study, the objective response rate and duration of response for treatment-naïve patients were 72% (95% CI=62, 85) and 44 months (95% CI=23.1, NE), with 15% experiencing a complete response and 59% experiencing a partial response, compared to 46% (95% CI=30, 63) and 18 months (95% CI=7.4, NE) in previously treated patients, with 10% experiencing a complete response and 36% experiencing a partial response (PMID: 37270692)."},{"alterations":["V600E","V600K"],"drugs":[{"ncitCode":"C77908","drugName":"Trametinib"}],"approvedIndications":["Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["29361468","25399551","22663011","25265492"],"abstracts":[],"description":"Trametinib is an oral small molecule inhibitor of MEK1/2 that is FDA-approved alone or with dabrafenib for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. In an open-label, randomized Phase III trial, patients with BRAF V600E/K-mutated unresectable, metastatic melanoma received oral trametinib (2 mg once daily) or an intravenous regimen of either dacarbazine (1000 mg/m2) or paclitaxel (175 mg/m2) every three weeks. Trametinib demonstrated improved progression-free survival (HR for disease progression or death = 0.45) and six-month overall survival (81% vs. 67%; death HR = 0.54; p=0.01) (PMID: 22663011). However, like other MEK inhibitors, the benefit of trametinib is limited by adverse reactions, most notably grade three or four rash and diarrhea (PMID: 22663011). Trametinib is not typically used as monotherapy for patients with BRAF V600K melanoma given its lower response rate compared to BRAF inhibitors and combined BRAF and MEK inhibitors. Patients previously treated with a RAF inhibitor appear to be less likely than untreated patients to respond to trametinib treatment (PMID: 22663011), and FDA guidelines state that trametinib as a monotherapy is not indicated for these patients. Dabrafenib and trametinib are FDA-approved as a combination therapy, which has superior clinical outcomes compared to dabrafenib or trametinib monotherapy (PMID: 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings had improved survival over patients given standard of care (PMID: 29361468)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"}],"approvedIndications":["Vemurafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["28961848","24508103","25399551"],"abstracts":[],"description":"Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. Vemurafenib has been shown to have nearly equivalent activity against melanomas with BRAF V600E and V600K mutations (PMID: 24508103). In a randomized Phase III trial comparing vemurafenib (960 mg orally twice daily) with dacarbazine (1000 mg/m2 i.v. every 3 weeks) for treatment-naive, metastatic, BRAF V600E-mutant melanoma, vemurafenib was associated with better overall survival (median survival 13.6 months vs. 9.7 months; hazard ratio 0.70, p=.0008) and longer median progression-free survival (6.9 months vs. 1.6 months) (PMID: 24508103). Final overall survival data from the BRIM-3 study showed that the survival advantage of vemurafenib over dacarbazine persisted through the 4-year landmark, with survival rates for vemurafenib and dacarbazine at the 4-year landmark being 17.0% and 15.6%, respectively (PMID: 28961848). However, a trial evaluating clinical outcomes in patients with melanoma treated with either combination therapy of dabrafenib and trametinib compared to those treated with vemurafenib monotherapy demonstrated improved survival outcomes in the combination-therapy group compared to the vemurafenib group (PMID: 25399551)."},{"alterations":["V600E","V600K"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":["Cobimetinib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma."],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["27480103","31732523","25265494"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim nine-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103), and five-year followup of the BRIM7 study showed a median overall survival of 31.8 months and a five-year survival rate of 39.2% (PMID: 31732523)."},{"alterations":["V600E","V600K"],"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib"},{"ncitCode":"C84865","drugName":"Binimetinib"}],"approvedIndications":["In combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation"],"level":"LEVEL_1","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":453,"code":"MEL","color":"Black","name":"Melanoma","mainType":{"id":null,"name":"Melanoma","tumorForm":"SOLID"},"tissue":"Skin","children":{},"parent":"SKIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["29573941","35862871"],"abstracts":[],"description":"The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA-approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single-agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI = 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI = 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI = 0.41-0.71; p<0·0001) (PMID: 29573941). In the five-year update of the Phase III COLUMBUS trial, the progression-free survival and overall survival were 23% and 35% respectively in the encorafenib plus binimetinib group (n=192) versus 10% and 21% respectively in the single agent vemurafenib group (n=191), and the median duration of response and disease control rate were 18.6 months and 92.2% in the encorafenib plus binimetinib group versus 12.3 months and 81.2% in the single-agent vemurafenib group (PMID: 35862871)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C66939","drugName":"Selumetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":407,"code":"PAST","color":"Gray","name":"Pilocytic Astrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["31151904"],"abstracts":[],"description":"Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":276,"code":"HCL","color":"LimeGreen","name":"Hairy Cell Leukemia","mainType":{"id":null,"name":"Mature B-Cell Neoplasms","tumorForm":"LIQUID"},"tissue":"Lymphoid","children":{},"parent":"MBN","level":5,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["26352686"],"abstracts":[],"description":"Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with various BRAF V600-harboring tumors, including melanoma and Edheim-Chester Disease (ECD). Vemurafenib is listed as a 2A therapeutic in the NCCN guidelines for Hairy Cell Leukemia (HCL) based on data from two Phase II trials. In one study of vemurafenib in patients with BRAF V600E-mutant HCL (n=24), the overall response rate was 100%, with 42% of patients (10 of 24) having complete responses, with a response duration of 11.7 months and one year progression free and overall survival rates of 73% and 91%, repectively (PMID: 26352686). In another study of vemurafenib in patients with BRAF V600E-mutant HCL (n=26), the overall response rate was 96%, with 35% of patients (9 of 26) having complete responses (PMID: 26352686)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":862,"code":"LCH","color":"LightSalmon","name":"Langerhans Cell Histiocytosis","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":"HDCN","level":4,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["32985015","29188284","30154124"],"abstracts":[],"description":"Vemurafenib is an orally available, small molecule RAF-targeted inhibitor that is FDA-approved for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib and dabrafenib are listed as monotherapies in the NCCN Histiocytic Neoplasms Guidelines (V3.2024) under the section \"Principles of Systemic Therapy\" as recommended treatment regimens for patients with Langerhans cell histiocytosis (LCH) harboring BRAF V600E mutations. NCCN recommendation was based on the results of the Phase II VE-BASKET (NCT01524978) and case reports.\nIn the Phase II VE-BASKET (NCT01524978) trial, all four patients of the LCH cohort achieved partial response (PMID: 29188284). In the case series evaluating the use of BRAF inhibitors in six adult patients with BRAF V600E‐mutant LCH, patients treated with vemurafenib monotherapy (n=3) achieved one complete response (CR), one partial response (PR) and one stable disease (SD) response while patients treated with dabrafenib monotherapy (n=3) achieved one CR and two PRs (PMID: 32985015). In a separate case report, a patient with BRAF V600E-mutant LCH was treated with dabrafenib plus trametinib and demonstrated a sustained metabolic response (PMID: 30154124)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":619,"code":"DIFG","color":"Gray","name":"Diffuse Glioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"BRAIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[{"id":753,"code":"DIPG","color":"Gray","name":"Diffuse Intrinsic Pontine Glioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"},{"id":855,"code":"DASTR","color":"Gray","name":"Diffuse Astrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"},{"id":296,"code":"AODG","color":"Gray","name":"Anaplastic Oligodendroglioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"},{"id":635,"code":"ODG","color":"Gray","name":"Oligodendroglioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"},{"id":332,"code":"OAST","color":"Gray","name":"Oligoastrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"},{"id":223,"code":"ASTR","color":"Gray","name":"Astrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"DIFG","level":3,"tumorForm":"SOLID"}],"pmids":["24725538","29039591","30462564","34232949","29621181","30351999","26287849","33117675"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with BRAF V600E-positive melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Three out of five patients with anaplastic astrocytoma had a response (one partial response, two stable disease) to vemurafenib monotherapy (PMID: 30351999). One patient with high-grade glioma (NOS) had stable disease in response to vemurafenib monotherapy (PMID:30351999). Four out of eight patients with glioma (NOS) had a response (one partial response, three stable disease, two progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 26287849). One patient with anaplastic oligoastrocytoma had stable disease in response to vemurafenib monotherapy (PMID: 30462564). Four of seven patients with glioblastoma multiforme had a response (one complete response, three stable disease, one progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 30351999, 24725538). Four patients with glioblastoma (including epithelioid glioblastoma) had a response (one “near-complete” response, three stable disease) to either dabrafenib monotherapy (n=2) or vemurafenib monotherapy (n=2) (PMID: 29621181, 29039591, 33117675, 34232949)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":54,"code":"ENCG","color":"Gray","name":"Encapsulated Glioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"BRAIN","level":2,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["25524464","29039591","31985841","25092772","31502039","27398937","29380516","28984141","24821190","30351999","26579623","26287849"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Six patients with ganglioglioma had a partial response to either vemurafenib monotherapy (n=2), vemurafenib + cobimetinib (n=1), or dabrafenib monotherapy (n=​​3)(PMID: 25524464, 31985841, 26579623, 31502039). Twelve out of thirteen patients with pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, six partial response, four stable disease) to either dabrafenib + trametinib (n=2) or vemurafenib monotherapy (n=11) (PMID: 28984141, 26287849, 30351999). Three patients with anaplastic pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, one partial response) to either vemurafenib monotherapy (n=1) or dabrafenib monotherapy (n=2)(PMID: 25092772, 29039591). One patient with low-grade glioma, NOS had a partial response to dabrafenib monotherapy (PMID: 27398937). Two patients with pilocytic astrocytoma had a response (one partial response, one stable disease) to vemurafenib monotherapy (PMID: 30351999). Three of four patients with anaplastic ganglioglioma had a response (one partial response, one \"significant response\", one stable disease, one not evaluable) to either dabrafenib + trametinib (n=1) or vemurafenib monotherapy (n=3)(PMID: 29380516, 30351999). One patient with pilomyxoid astrocytoma had a partial response to vemurafenib monotherapy (PMID: 24821190)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":32,"code":"PXA","color":"Gray","name":"Pleomorphic Xanthoastrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["30120137","29380516","28984141"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-compendium listed as recommended treatment of central nervous system cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a sixteen-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":407,"code":"PAST","color":"Gray","name":"Pilocytic Astrocytoma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["30120137","29380516","28984141"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-compendium listed as recommended treatment of central nervous system cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a sixteen-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"},{"ncitCode":"C68923","drugName":"Cobimetinib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":669,"code":"GNG","color":"Gray","name":"Ganglioglioma","mainType":{"id":null,"name":"Glioma","tumorForm":"SOLID"},"tissue":"CNS/Brain","children":{},"parent":"ENCG","level":3,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["30120137","29380516","28984141"],"abstracts":[],"description":"The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-compendium listed as recommended treatment of central nervous system cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a sixteen-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":862,"code":"LCH","color":"LightSalmon","name":"Langerhans Cell Histiocytosis","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":"HDCN","level":4,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["32985015","29188284","30154124"],"abstracts":[],"description":"Vemurafenib is an orally available, small molecule RAF-targeted inhibitor that is FDA-approved for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib and dabrafenib are listed as monotherapies in the NCCN Histiocytic Neoplasms Guidelines (V3.2024) under the section \"Principles of Systemic Therapy\" as recommended treatment regimens for patients with Langerhans cell histiocytosis (LCH) harboring BRAF V600E mutations. NCCN recommendation was based on the results of the Phase II VE-BASKET (NCT01524978) and case reports.\nIn the Phase II VE-BASKET (NCT01524978) trial, all four patients of the LCH cohort achieved partial response (PMID: 29188284). In the case series evaluating the use of BRAF inhibitors in six adult patients with BRAF V600E‐mutant LCH, patients treated with vemurafenib monotherapy (n=3) achieved one complete response (CR), one partial response (PR) and one stable disease (SD) response while patients treated with dabrafenib monotherapy (n=3) achieved one CR and two PRs (PMID: 32985015). In a separate case report, a patient with BRAF V600E-mutant LCH was treated with dabrafenib plus trametinib and demonstrated a sustained metabolic response (PMID: 30154124)."},{"alterations":["V600E"],"drugs":[{"ncitCode":"C98283","drugName":"Encorafenib"},{"ncitCode":"C1857","drugName":"Panitumumab"}],"approvedIndications":[],"level":"LEVEL_2","fdaLevel":"LEVEL_Fda2","levelAssociatedCancerType":{"id":935,"code":"","color":"SaddleBrown","name":"","mainType":{"id":null,"name":"Colorectal Cancer","tumorForm":"SOLID"},"tissue":"Bowel","children":{},"parent":null,"level":0,"tumorForm":"SOLID"},"levelExcludedCancerTypes":[],"pmids":["29431699","31566309"],"abstracts":[],"description":"Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed in combination as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C64768","drugName":"Vemurafenib"}],"approvedIndications":[],"level":"LEVEL_3A","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":934,"code":"","color":"LightSalmon","name":"","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":null,"level":0,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["31376203","31213430","25209580"],"abstracts":[],"description":"Vemurafenib is an orally available, small molecule RAF-targeted inhibitor that is FDA-approved for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib and dabrafenib are listed as monotherapies in the NCCN Histiocytic Neoplasms Guidelines (V3.2024) under the section \"Principles of Systemic Therapy\" as recommended treatment regimens for patients with ECD and Langerhans cell histiocytosis (LCH) harboring BRAF V600E mutations. There is promising clinical data to support the use of vemurafenib and dabrafenib as monotherapies in patients with non-ECD and non-LCH BRAF V600-mutant histiocytic neoplasms.\nIn a case study, a patient with heterozygous BRAF V600E-mutant histiocytic sarcoma was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a second case study, a patient with BRAF V600E-mutant histiocytic sarcoma was treated with vemurafenib plus chemotherapy, antibiotics and steroids and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). In a third case study, a pediatric patient with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and LCH reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."},{"alterations":["V600"],"drugs":[{"ncitCode":"C82386","drugName":"Dabrafenib"}],"approvedIndications":[],"level":"LEVEL_3A","fdaLevel":"LEVEL_Fda3","levelAssociatedCancerType":{"id":934,"code":"","color":"LightSalmon","name":"","mainType":{"id":null,"name":"Histiocytosis","tumorForm":"LIQUID"},"tissue":"Myeloid","children":{},"parent":null,"level":0,"tumorForm":"LIQUID"},"levelExcludedCancerTypes":[],"pmids":["31376203","31213430","25209580"],"abstracts":[],"description":"Vemurafenib is an orally available, small molecule RAF-targeted inhibitor that is FDA-approved for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation. Vemurafenib and dabrafenib are listed as monotherapies in the NCCN Histiocytic Neoplasms Guidelines (V3.2024) under the section \"Principles of Systemic Therapy\" as recommended treatment regimens for patients with ECD and Langerhans cell histiocytosis (LCH) harboring BRAF V600E mutations. There is promising clinical data to support the use of vemurafenib and dabrafenib as monotherapies in patients with non-ECD and non-LCH BRAF V600-mutant histiocytic neoplasms.\nIn a case study, a patient with heterozygous BRAF V600E-mutant histiocytic sarcoma was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a second case study, a patient with BRAF V600E-mutant histiocytic sarcoma was treated with vemurafenib plus chemotherapy, antibiotics and steroids and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). In a third case study, a pediatric patient with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and LCH reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."}],"dataVersion":"v4.27","lastUpdate":"03/13/2025","vus":false}